Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.24 AUD | 0.00% | 0.00% | +2.13% |
28/02 | Transcript : Capitol Health Limited, H1 2024 Earnings Call, Feb 29, 2024 | |
28/02 | Capitol Health Posts 20% Rise in H1 FY24 Revenue, Returns to Profit | MT |
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company is in debt and has limited leeway for investment
- With a 2024 P/E ratio at 29.67 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.13% | 168M | C | ||
-17.08% | 8.39B | B+ | ||
+45.61% | 3.74B | C+ | ||
-36.69% | 2.55B | B- | ||
-9.28% | 2.48B | - | ||
-13.43% | 2.32B | B- | ||
-6.49% | 1.93B | C- | ||
-17.24% | 1.6B | A- | ||
-37.21% | 1.28B | C+ | ||
+5.14% | 1.08B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CAJ Stock
- Ratings Capitol Health Limited